These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 3171705)

  • 1. Heparin-induced platelet factor 4 release by serial heparin injections.
    Stevanato F; Paolini R; Sgarbossa G; Simioni P; Cella G
    J Nucl Med Allied Sci; 1988; 32(2):106-9. PubMed ID: 3171705
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of increasing heparin doses and of heparinoid on platelet factor 4 (PF4) release in normal subjects.
    Randi ML; Fabris F; Casonato A; Scattolo N; Cella G; Girolami A
    Haematologica; 1984; 69(2):141-7. PubMed ID: 6429001
    [No Abstract]   [Full Text] [Related]  

  • 3. [Heparin management by activated coagulation time during cardiopulmonary bypass].
    Shikano K; Shinpo H; Nasu M; Morimoto T; Suzuki T; Yada I; Kusagawa M
    Kyobu Geka; 1981; 34(12):934-7. PubMed ID: 7349352
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant platelet factor 4 for heparin neutralization.
    Mixon TA; Dehmer GJ
    Semin Thromb Hemost; 2004 Jun; 30(3):369-77. PubMed ID: 15282660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Mar; 85(3):346-53. PubMed ID: 6827843
    [No Abstract]   [Full Text] [Related]  

  • 7. Intra-platelet platelet factor 4 (IP.PF4) and the heparin-mobilisable pool of PF4 in health and atherosclerosis.
    O'Brien JR; Etherington MD; Pashley M
    Thromb Haemost; 1984 Jul; 51(3):354-7. PubMed ID: 6495255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times.
    Brack MJ; More RS; Hubner PJ; Gershlick AH
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):183-6. PubMed ID: 8457649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged heparin administration during clopidogrel treatment in healthy subjects.
    Caplain H; D'Honneur G; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():61-4. PubMed ID: 10440426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications of low-dose heparin prophylaxis in gynecologic oncology surgery.
    Clarke-Pearson DL; DeLong ER; Synan IS; Creasman WT
    Obstet Gynecol; 1984 Nov; 64(5):689-94. PubMed ID: 6493660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heparin-free hemodialysis in chronic patients for temporary management of conditions with a high risk of bleeding].
    Stradtmann H; Förster S; Jalinski W
    Z Urol Nephrol; 1988 Jul; 81(7):449-53. PubMed ID: 3176720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of anti-platelet factor 4/heparin antibodies after cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status.
    Paparella D; Scrascia G; Galeone A; Coviello M; Cappabianca G; Venneri MT; Favoino B; Quaranta M; Schinosa Lde L; Warkentin TE
    J Thorac Cardiovasc Surg; 2008 Dec; 136(6):1456-63. PubMed ID: 19114189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements.
    White RH; Zhou H; Woo L; Mungall D
    Arch Intern Med; 1997 Nov; 157(21):2468-72. PubMed ID: 9385298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limits of APTT for monitoring heparin.
    Vine DL
    Kans Med; 1993 Jan; 94(1):23-4. PubMed ID: 8433544
    [No Abstract]   [Full Text] [Related]  

  • 17. Anticoagulation by constant subcutaneous heparin infusion.
    Parrilla N; Ansell J
    Thromb Haemost; 1982 Feb; 47(1):1-2. PubMed ID: 7071800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
    Alexander JH; Yang H; Becker RC; Kodama K; Goodman S; Dyke CK; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Burton JR; Bovill EG; Kawai C; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2005 Mar; 3(3):439-47. PubMed ID: 15748230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory monitoring of heparin therapy.
    Wittkowsky AK
    Clin Pharm; 1991 Nov; 10(11):824. PubMed ID: 1794218
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans.
    Dehmer GJ; Lange RA; Tate DA; Pirwitz M; Daniel W; Fisher M; Bonnem EM
    Circulation; 1996 Nov; 94(9 Suppl):II347-52. PubMed ID: 8901773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.